Mode
Text Size
Log in / Sign up
N/A N=51 Double-blind Treatment

Effect of Neural Mobilization on Lumbosacral Radiculopathy Patients With Peripheral Sensitization

Radiculopathy

Enrolled (actual)
51
Serious AEs
0.0%
Results posted
Jul 2019
Primary outcome: Primary: Visual Analog Scale — 5.638; 5.050; 5.094; 4.894 Centimeters

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Neural mobilization exercises -Tensioner technique (Other); Neural mobilization exercises -Slider technique (Other); Transcutaneous Electrical Nerve Stimulation (TENS) (Other)
Age
Adult · 18+ yrs
Sex
Male
Sponsor
Mohammed Al-Ghamdi
Primary completion
Nov 2017

Outcome Measures

OutcomeResultp-value
PRIMARY
Visual Analog Scale
5.638; 5.050; 5.094; 4.894; 4.759; 3.576
PRIMARY
Hip Flexion Range of Motion (Symptomatic Side)
51.82; 57.71; 46.29; 58.53; 63.59; 58.88
PRIMARY
Knee Flexion Range of Motion (Symptomatic Side)
52.29; 45.647; 47.059; 49.41; 31.294; 34.824
PRIMARY
Hip Flexion Range of Motion (Asymptomatic Side)
70.00; 71.824; 63.59; 69.41; 70.82; 69.12
PRIMARY
Knee Flexion Range of Motion (Asymptomatic Side)
31.1176; 31.7059; 28.8824; 30.41; 24.06; 26.06

Summary

The primary purpose of this study was to investigate the effects of slider and tensioner techniques on pain, hip and knee ROM in lumbosacral radiculopathy patients with peripheral sensitization. A secondary purpose was to evaluate the correlation between these outcomes measurements.

Eligibility Criteria

Inclusion Criteria

  • Patients with lumbosacral radiculopathy with dominant peripheral sensitization
  • patients with unilateral leg pain.
  • patient S-LANSS score > 12,
  • negative sensory and motor examination.
  • positive neural tissue provocation tests (straight leg raising test, slump test).
  • adult.
  • pain duration of more than 3 months.

Exclusion Criteria

  • S-LANSS score ≥ 12,
  • motor or sensory deficits,
  • history of back or lower extremity surgeries,
  • bilateral referred pain,
  • patients with pacemakers, cardiovascular problems, epilepsy, active malignancy, dermatological conditions, and diminished pain sensation.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03621878). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search